@entity2915 following postnatal @entity143 antagonist treatment: reversal by XXXX .

@entity2254 @entity2227 @entity1024 @entity19 @entity71 @entity3652 @entity51 @entity2915 @entity143 @entity1613 @entity3390 @entity1068 @entity734
Three experiments were performed to study the effects of neonatal administration of @entity2227 receptor antagonists, on either Day 11 ( @entity3390 = @entity3390 , 3 x 0.5 mg/kg, s.c., injected at 0800, 1600 and 2400 h) or Day 10 ( @entity3652 , 1 x 50 mg/kg, s.c., or @entity1068 -Low, 1 x 2.5 mg/kg, or, @entity1068 -High, 2 x 2.5 mg/kg, s.c., with 2-h interval) to male @entity19 pups, on spontaneous motor behavior, @entity734 to a novel situation and @entity2254 -induced activity in the adult animals. @entity19 administered @entity3390 showed @entity1613 followed by @entity2915 over the later (20-40 and 40-60 min) periods of testing. @entity19 administered @entity3652 and @entity1068 -High similarly displayed an @entity1613 followed by @entity2915 over the later time (20-60 min) of testing. @entity734 to the novel activity test chambers was reduced drastically in the @entity3390 @entity19 compared with vehicle-treated @entity19 . Similarly, @entity19 administered @entity3652 and @entity1068 -High displayed too drastically reduced @entity734 behavior. The low dose of @entity2254 (0.25 mg/kg) reduced the @entity2915 of neonatal @entity3390 -treated @entity19 , particularly from 30-60 min onwards, and elevated the activity level of the vehicle-treated @entity19 . Similarly, the low dose of @entity2254 (0.25 mg/kg) reduced the @entity2915 of neonatally @entity3652 -treated and @entity1068 -High-treated @entity19 , particularly from 30-60 min onwards, and elevated the activity level of the respective vehicle-treated @entity19 . Fluoro-jade staining per mm(2) regional brain tissue of @entity3390 @entity19 pups expressed as percent of vehicle @entity19 pups showed also that the extensiveness of staining was markedly greater in the parietal cortex, hippocampus, frontal cortex, and lesser so in the laterodorsal thalamus. @entity3652 -treated @entity19 showed cell degeneration mainly in the parietal cortex, whereas the @entity1068 -High @entity19 showed marked cell degeneration in both the parietal and laterodorsal cortex. The present findings that encompass a pattern of regional neuronal degeneration, disruptions of spontaneous motor activity, @entity51 and reversal of @entity2915 by a low dose of @entity2254 suggest a model of @entity71 that underlines the intimate role of @entity1024 ( @entity143 ) receptors in the developing brain.
